PubMed:22988862
Annnotations
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-76 | Sentence | denotes | Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2. |
T2 | 77-189 | Sentence | denotes | Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most common genetic cause of PD (Parkinson's disease). |
T3 | 190-336 | Sentence | denotes | To investigate how mutations in LRRK2 cause PD, we generated LRRK2 mutant mice either lacking its expression or expressing the R1441C mutant form. |
T4 | 337-720 | Sentence | denotes | Homozygous R1441C knockin mice exhibit no dopaminergic neurodegeneration or alterations in steady-state levels of striatal dopamine, but they show impaired dopamine neurotransmission, as was evident from reductions in amphetamine-induced locomotor activity and stimulated catecholamine release in cultured chromaffin cells as well as impaired dopamine D2 receptor-mediated functions. |
T5 | 721-1013 | Sentence | denotes | Whereas LRRK2-/- brains are normal, LRRK2-/- kidneys at 20 months of age develop striking accumulation and aggregation of α-synuclein and ubiquitinated proteins, impairment of the autophagy-lysosomal pathway, and increases in apoptotic cell death, inflammatory responses and oxidative damage. |
T6 | 1014-1236 | Sentence | denotes | Our further analysis of LRRK2-/- kidneys at multiple ages revealed unique age-dependent biphasic alterations of the autophagic activity, which is unchanged at 1 month of age, enhanced at 7 months, but reduced at 20 months. |
T7 | 1237-1375 | Sentence | denotes | Levels of α-synuclein and protein carbonyls, a general oxidative damage marker, are also decreased in LRRK2-/- kidneys at 7 months of age. |
T8 | 1376-1565 | Sentence | denotes | Interestingly, this biphasic alteration is associated with increased levels of lysosomal proteins and proteases as well as progressive accumulation of autolysosomes and lipofuscin granules. |
T9 | 1566-1750 | Sentence | denotes | We conclude that pathogenic mutations in LRRK2 impair the nigrostriatal dopaminergic pathway, and LRRK2 plays an essential role in the dynamic regulation of autophagy function in vivo. |
T1 | 0-76 | Sentence | denotes | Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2. |
T2 | 77-189 | Sentence | denotes | Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most common genetic cause of PD (Parkinson's disease). |
T3 | 190-336 | Sentence | denotes | To investigate how mutations in LRRK2 cause PD, we generated LRRK2 mutant mice either lacking its expression or expressing the R1441C mutant form. |
T4 | 337-720 | Sentence | denotes | Homozygous R1441C knockin mice exhibit no dopaminergic neurodegeneration or alterations in steady-state levels of striatal dopamine, but they show impaired dopamine neurotransmission, as was evident from reductions in amphetamine-induced locomotor activity and stimulated catecholamine release in cultured chromaffin cells as well as impaired dopamine D2 receptor-mediated functions. |
T5 | 721-1013 | Sentence | denotes | Whereas LRRK2-/- brains are normal, LRRK2-/- kidneys at 20 months of age develop striking accumulation and aggregation of α-synuclein and ubiquitinated proteins, impairment of the autophagy-lysosomal pathway, and increases in apoptotic cell death, inflammatory responses and oxidative damage. |
T6 | 1014-1236 | Sentence | denotes | Our further analysis of LRRK2-/- kidneys at multiple ages revealed unique age-dependent biphasic alterations of the autophagic activity, which is unchanged at 1 month of age, enhanced at 7 months, but reduced at 20 months. |
T7 | 1237-1375 | Sentence | denotes | Levels of α-synuclein and protein carbonyls, a general oxidative damage marker, are also decreased in LRRK2-/- kidneys at 7 months of age. |
T8 | 1376-1565 | Sentence | denotes | Interestingly, this biphasic alteration is associated with increased levels of lysosomal proteins and proteases as well as progressive accumulation of autolysosomes and lipofuscin granules. |
T9 | 1566-1750 | Sentence | denotes | We conclude that pathogenic mutations in LRRK2 impair the nigrostriatal dopaminergic pathway, and LRRK2 plays an essential role in the dynamic regulation of autophagy function in vivo. |
c_corpus
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 20-39 | D010300 | denotes | Parkinson's disease |
T6 | 20-39 | D010300 | denotes | Parkinson's disease |
T10 | 47-54 | 6308 | denotes | leucine |
T11 | 47-54 | SO:0001437 | denotes | leucine |
T9 | 47-54 | CHEBI:15603 | denotes | leucine |
T12 | 47-54 | D007930 | denotes | leucine |
T13 | 47-54 | CHEBI:25017 | denotes | leucine |
T14 | 47-54 | D007930 | denotes | leucine |
T15 | 60-66 | SO:0001068 | denotes | repeat |
T16 | 90-95 | PR:Q5S006 | denotes | LRRK2 |
T17 | 90-95 | PR:000003033 | denotes | LRRK2 |
T18 | 90-95 | PR:Q5S007 | denotes | LRRK2 |
T20 | 97-104 | 6308 | denotes | leucine |
T21 | 97-104 | SO:0001437 | denotes | leucine |
T19 | 97-104 | CHEBI:15603 | denotes | leucine |
T22 | 97-104 | D007930 | denotes | leucine |
T23 | 97-104 | CHEBI:25017 | denotes | leucine |
T24 | 97-104 | D007930 | denotes | leucine |
T25 | 110-116 | SO:0001068 | denotes | repeat |
T30 | 168-187 | D010300 | denotes | Parkinson's disease |
T31 | 168-187 | D010300 | denotes | Parkinson's disease |
T34 | 222-227 | PR:Q5S006 | denotes | LRRK2 |
T35 | 222-227 | PR:000003033 | denotes | LRRK2 |
T36 | 222-227 | PR:Q5S007 | denotes | LRRK2 |
T37 | 251-256 | PR:Q5S006 | denotes | LRRK2 |
T38 | 251-256 | PR:000003033 | denotes | LRRK2 |
T39 | 251-256 | PR:Q5S007 | denotes | LRRK2 |
T40 | 264-268 | PR:000005054 | denotes | mice |
T42 | 264-268 | O89094 | denotes | mice |
T41 | 264-268 | D051379 | denotes | mice |
T43 | 264-268 | 10095 | denotes | mice |
T44 | 363-367 | PR:000005054 | denotes | mice |
T46 | 363-367 | O89094 | denotes | mice |
T45 | 363-367 | D051379 | denotes | mice |
T47 | 363-367 | 10095 | denotes | mice |
T52 | 460-468 | 3628 | denotes | dopamine |
T48 | 460-468 | CHEBI:59905 | denotes | dopamine |
T49 | 460-468 | CHEBI:18243 | denotes | dopamine |
T50 | 460-468 | D004298 | denotes | dopamine |
T51 | 460-468 | D004298 | denotes | dopamine |
T57 | 493-501 | 3628 | denotes | dopamine |
T53 | 493-501 | CHEBI:59905 | denotes | dopamine |
T54 | 493-501 | CHEBI:18243 | denotes | dopamine |
T55 | 493-501 | D004298 | denotes | dopamine |
T56 | 493-501 | D004298 | denotes | dopamine |
T58 | 502-519 | GO:0007268 | denotes | neurotransmission |
T64 | 555-566 | 725 | denotes | amphetamine |
T59 | 555-566 | D000661 | denotes | amphetamine |
T60 | 555-566 | CHEBI:42724 | denotes | amphetamine |
T61 | 555-566 | CHEBI:2679 | denotes | amphetamine |
T62 | 555-566 | D000661 | denotes | amphetamine |
T63 | 555-566 | CHEBI:4469 | denotes | amphetamine |
T65 | 609-622 | CHEBI:33567 | denotes | catecholamine |
T66 | 643-659 | UBERON:0001236 | denotes | chromaffin cells |
T71 | 680-688 | 3628 | denotes | dopamine |
T72 | 680-700 | P20288 | denotes | dopamine D2 receptor |
T73 | 680-700 | P52702 | denotes | dopamine D2 receptor |
T74 | 680-700 | P14416 | denotes | dopamine D2 receptor |
T75 | 680-700 | P61169 | denotes | dopamine D2 receptor |
T76 | 680-700 | Q9GJU1 | denotes | dopamine D2 receptor |
T77 | 680-700 | PR:000001177 | denotes | dopamine D2 receptor |
T78 | 680-700 | P61168 | denotes | dopamine D2 receptor |
T79 | 680-700 | Q6TLI9 | denotes | dopamine D2 receptor |
T81 | 680-700 | O73810 | denotes | dopamine D2 receptor |
T82 | 680-700 | P60026 | denotes | dopamine D2 receptor |
T80 | 680-700 | D017448 | denotes | dopamine D2 receptor |
T83 | 729-734 | PR:Q5S006 | denotes | LRRK2 |
T84 | 729-734 | PR:000003033 | denotes | LRRK2 |
T85 | 729-734 | PR:Q5S007 | denotes | LRRK2 |
T86 | 757-762 | PR:Q5S006 | denotes | LRRK2 |
T87 | 757-762 | PR:000003033 | denotes | LRRK2 |
T88 | 757-762 | PR:Q5S007 | denotes | LRRK2 |
T91 | 845-854 | P37379 | denotes | synuclein |
T90 | 845-854 | D051843 | denotes | synuclein |
T92 | 859-881 | D057149 | denotes | ubiquitinated proteins |
T94 | 901-910 | GO:0016236 | denotes | autophagy |
T95 | 901-910 | GO:0006914 | denotes | autophagy |
T96 | 921-928 | CHEBI:34922 | denotes | pathway |
T97 | 947-967 | GO:0006915 | denotes | apoptotic cell death |
T99 | 1038-1043 | PR:Q5S006 | denotes | LRRK2 |
T100 | 1038-1043 | PR:000003033 | denotes | LRRK2 |
T101 | 1038-1043 | PR:Q5S007 | denotes | LRRK2 |
T132 | 1249-1258 | P37379 | denotes | synuclein |
T131 | 1249-1258 | D051843 | denotes | synuclein |
T136 | 1263-1270 | PR:000000001 | denotes | protein |
T133 | 1263-1270 | GO:0003675 | denotes | protein |
T137 | 1263-1270 | SO:0000104 | denotes | protein |
T134 | 1263-1270 | CHEBI:36080 | denotes | protein |
T135 | 1263-1270 | CHEBI:11122 | denotes | protein |
T138 | 1339-1344 | PR:Q5S006 | denotes | LRRK2 |
T139 | 1339-1344 | PR:000003033 | denotes | LRRK2 |
T140 | 1339-1344 | PR:Q5S007 | denotes | LRRK2 |
T143 | 1455-1473 | C018589 | denotes | lysosomal proteins |
T145 | 1478-1487 | D010447 | denotes | proteases |
T146 | 1545-1555 | D008062 | denotes | lipofuscin |
T147 | 1545-1555 | D008062 | denotes | lipofuscin |
T148 | 1607-1612 | PR:Q5S006 | denotes | LRRK2 |
T149 | 1607-1612 | PR:000003033 | denotes | LRRK2 |
T150 | 1607-1612 | PR:Q5S007 | denotes | LRRK2 |
T151 | 1651-1658 | CHEBI:34922 | denotes | pathway |
T152 | 1664-1669 | PR:Q5S006 | denotes | LRRK2 |
T153 | 1664-1669 | PR:000003033 | denotes | LRRK2 |
T154 | 1664-1669 | PR:Q5S007 | denotes | LRRK2 |
T156 | 1709-1732 | GO:0010506 | denotes | regulation of autophagy |
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 168-177 | HP_0001300 | denotes | Parkinson |
T2 | 392-409 | HP_0002180 | denotes | neurodegeneration |
Allie
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
SS1_22988862_1_0 | 97-125 | expanded | denotes | leucine-rich repeat kinase 2 |
SS2_22988862_1_0 | 90-95 | abbr | denotes | LRRK2 |
SS1_22988862_1_1 | 168-187 | expanded | denotes | Parkinson's disease |
SS2_22988862_1_1 | 164-166 | abbr | denotes | PD |
AE1_22988862_1_0 | SS1_22988862_1_0 | SS2_22988862_1_0 | abbreviatedTo | leucine-rich repeat kinase 2,LRRK2 |
AE1_22988862_1_1 | SS1_22988862_1_1 | SS2_22988862_1_1 | abbreviatedTo | Parkinson's disease,PD |
UseCases_ArguminSci_Discourse
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-76 | DRI_Unspecified | denotes | Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2. |
T2 | 77-189 | DRI_Approach | denotes | Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most common genetic cause of PD (Parkinson's disease). |
T3 | 190-336 | DRI_Approach | denotes | To investigate how mutations in LRRK2 cause PD, we generated LRRK2 mutant mice either lacking its expression or expressing the R1441C mutant form. |
T4 | 337-720 | DRI_Background | denotes | Homozygous R1441C knockin mice exhibit no dopaminergic neurodegeneration or alterations in steady-state levels of striatal dopamine, but they show impaired dopamine neurotransmission, as was evident from reductions in amphetamine-induced locomotor activity and stimulated catecholamine release in cultured chromaffin cells as well as impaired dopamine D2 receptor-mediated functions. |
T5 | 721-1013 | DRI_Background | denotes | Whereas LRRK2-/- brains are normal, LRRK2-/- kidneys at 20 months of age develop striking accumulation and aggregation of α-synuclein and ubiquitinated proteins, impairment of the autophagy-lysosomal pathway, and increases in apoptotic cell death, inflammatory responses and oxidative damage. |
T6 | 1014-1236 | DRI_Approach | denotes | Our further analysis of LRRK2-/- kidneys at multiple ages revealed unique age-dependent biphasic alterations of the autophagic activity, which is unchanged at 1 month of age, enhanced at 7 months, but reduced at 20 months. |
T7 | 1237-1375 | DRI_Background | denotes | Levels of α-synuclein and protein carbonyls, a general oxidative damage marker, are also decreased in LRRK2-/- kidneys at 7 months of age. |
T8 | 1376-1565 | DRI_Challenge | denotes | Interestingly, this biphasic alteration is associated with increased levels of lysosomal proteins and proteases as well as progressive accumulation of autolysosomes and lipofuscin granules. |
T9 | 1566-1750 | DRI_Outcome | denotes | We conclude that pathogenic mutations in LRRK2 impair the nigrostriatal dopaminergic pathway, and LRRK2 plays an essential role in the dynamic regulation of autophagy function in vivo. |
PubMed_ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 77-189 | DRI_Approach | denotes | Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most common genetic cause of PD (Parkinson's disease). |
T2 | 190-336 | DRI_Approach | denotes | To investigate how mutations in LRRK2 cause PD, we generated LRRK2 mutant mice either lacking its expression or expressing the R1441C mutant form. |
T3 | 337-720 | DRI_Background | denotes | Homozygous R1441C knockin mice exhibit no dopaminergic neurodegeneration or alterations in steady-state levels of striatal dopamine, but they show impaired dopamine neurotransmission, as was evident from reductions in amphetamine-induced locomotor activity and stimulated catecholamine release in cultured chromaffin cells as well as impaired dopamine D2 receptor-mediated functions. |
T4 | 721-1013 | DRI_Background | denotes | Whereas LRRK2-/- brains are normal, LRRK2-/- kidneys at 20 months of age develop striking accumulation and aggregation of α-synuclein and ubiquitinated proteins, impairment of the autophagy-lysosomal pathway, and increases in apoptotic cell death, inflammatory responses and oxidative damage. |
T5 | 1014-1236 | DRI_Approach | denotes | Our further analysis of LRRK2-/- kidneys at multiple ages revealed unique age-dependent biphasic alterations of the autophagic activity, which is unchanged at 1 month of age, enhanced at 7 months, but reduced at 20 months. |
T6 | 1237-1375 | DRI_Background | denotes | Levels of α-synuclein and protein carbonyls, a general oxidative damage marker, are also decreased in LRRK2-/- kidneys at 7 months of age. |
T7 | 1376-1565 | DRI_Challenge | denotes | Interestingly, this biphasic alteration is associated with increased levels of lysosomal proteins and proteases as well as progressive accumulation of autolysosomes and lipofuscin granules. |
T8 | 1566-1750 | DRI_Outcome | denotes | We conclude that pathogenic mutations in LRRK2 impair the nigrostriatal dopaminergic pathway, and LRRK2 plays an essential role in the dynamic regulation of autophagy function in vivo. |
DisGeNET5_gene_disease
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
22988862-0#47#75#gene120892 | 47-75 | gene120892 | denotes | leucine-rich repeat kinase 2 |
22988862-0#20#39#diseaseC0030567 | 20-39 | diseaseC0030567 | denotes | Parkinson's disease |
47#75#gene12089220#39#diseaseC0030567 | 22988862-0#47#75#gene120892 | 22988862-0#20#39#diseaseC0030567 | associated_with | leucine-rich repeat kinase 2,Parkinson's disease |
PubTator4TogoVar
Id | Subject | Object | Predicate | Lexical cue | proteinmutation |
---|---|---|---|---|---|
22988862_0 | 350-356 | ProteinMutation | denotes | 441C k | rs33939927 |
22988862_1 | 319-325 | ProteinMutation | denotes | 441C m | rs33939927 |